Abstract
Background
Gastric cancer with peritoneal metastasis (PM-GC), recognized as one of the deadliest cancers. However, whether and how the tumor cell-extrinsic tumor microenvironment (TME) is involved in the therapeutic failure remains unknown. Thus, this study systematically assessed the immunosuppressive tumor microenvironment in ascites from patients with PM-GC, and its contribution to dissemination and immune evasion of ascites-disseminated tumor cells (aDTCs).
Methods
Sixty-three ascites and 43 peripheral blood (PB) samples from 51 patients with PM-GC were included in this study. aDTCs in ascites and circulating tumor cells (CTCs) in paired PB were immunophenotypically profiled. Using single-cell RNA transcriptional sequencing (scRNA-seq), crosstalk between aDTCs and the TME features of ascites was inspected. Further studies on the mechanism underlying aDTCs-immune cells crosstalk were performed on in vitro cultured aDTCs.
Results
Immune cells in ascites interact with aDTCs, prompting their immune evasion. Specifically, we found that the tumor-associated macrophages (TAMs) in ascites underwent a continuum lineage transition from cathepsinhigh (CTShigh) to complement 1qhigh (C1Qhigh) TAM. CTShigh TAM initially attracted the metastatic tumor cells to ascites, thereafter, transitioning terminally to C1Qhigh TAM to trigger overproliferation and immune escape of aDTCs. Mechanistically, we demonstrated that C1Qhigh TAMs significantly enhanced the expression of PD-L1 and NECTIN2 on aDTCs, which was driven by the activation of the C1q-mediated complement pathway.
Conclusions
For the first time, we identified an immunosuppressive macrophage transition from CTShigh to C1Qhigh TAM in ascites from patients with PM-GC. This may contribute to developing potential TAM-targeted immunotherapies for PM-GC.
Graphical Abstract
Schematic of the immune TME of ascites and the crosstalk with aDTCs in patients with PM-GC. In ascites with TAM-dominant TME, the ascitic TAMs undergo CTS-to-C1Q transition to support multiple phases of aDTC dissemination, including aDTC homing, proliferation, immune escape, and therapeutic resistance. While in ascites with T-cell-dominant TME, enriched T cells do not imply “immune-hot” TME. Infiltrated CD8+ T cells are GZMK+ precursor-exhausted cells that have lost their capacity to kill tumor cells. (Abbreviations: aDTC ascites-disseminated tumor cells, CTS cathepsin, TAM Tumor-associated macrophages, TME tumor microenvironment)
Similar content being viewed by others
Introduction
Peritoneal metastasis (PM), a fatal type of fatal metastasis, can develop in over 15% of patients with gastric cancer (GC) [1]. However, chemotherapies and targeted therapies have failed to prevent GC with peritoneal carcinomatosis (PM-GC) onset [2, 3]. Although recent immunotherapies have achieved excellent success in other cancers, including non-small-cell lung cancer [4], melanoma [5], and microsatellite instability-high (MSI-H) colorectal cancer [6], their effectiveness is limited in patients with PM-GC [7], indicating the high immunosuppressive characteristics of PM-GC.
PM-GC presents clinical therapeutic resistance to the increased cell-intrinsic aggressiveness of metastatic tumor cells [8,9,10,11]. Tumor cells disseminating into malignant ascites, i.e., ascites-disseminated tumor cells (aDTCs), are associated with high epithelial-to-mesenchymal plasticity [8, 9], continuous transcriptional activation, and transforming growth factor-β (TGF-β) pathway activation [8], possibly upregulating immune checkpoints and consequently inducing aDTC immune evasion from immune surveillance and immunotherapeutic pressure [8]. Moreover, evidence from other cancers suggests that the tumor microenvironment (TME), especially immune cells in the TME, can interplay with tumor cells, immunoediting their malignancy and resistance to therapeutic pressures [12]. Furthermore, tumor-associated macrophages (TAMs) are “pro-tumor” immune cells in high numbers in the TME [13] and are crucial in maintaining cancer stem cell (CSC) stemness; for instance, in breast cancer, TAMs can secrete regulatory mediators, including transforming growth factor-β1 (TGF-β1), to improve CSC epithelial-to-mesenchymal transition, prompting their tolerance to treatment pressures [14]. Additionally, juxtacrine secreted from glioblastoma TAMs activates PTPRZ1 signaling in glioblastoma CSCs, fostering tumor growth [15]. However, the TME composition in peritoneally metastatic niches in PM-GC remains poorly understood [16]. Furthermore, how immunosuppressive TME components, including TAMs, affect tumor-cell immune evasion and immunotherapeutic resistance in PM-GC remains unclear.
Thus, this systematic study assessed immune cells in the TME and their interaction with aDTCs based on three independent PM-GC cohorts containing 63 ascites from 51 patients with GC and provided a new perspective for immunotherapy in PM-GC by targeting the TAM transition and its crosstalk.
Materials and methods
Specimen collection
This study was conducted at Peking University Cancer Hospital, Bei Jing, China from July 2019 to June 2021. The study used three independent cohorts with 63 ascites and 43 peripheral blood samples from 51 patients with PM-GC (Supplementary Fig. S1). Detailed information regarding the three cohorts, subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH), single-cell RNA sequencing (scRNA-seq) test, and scRNA-seq validation, is shown in Supplementary Fig. S1 and supplementary materials and methods.
aDTCs or circulating tumor cells (CTCs) enrichment by SE-iFISH
The ascites and matched paired peripheral blood (PB) samples in the SE-iFISH cohort were subjected to aDTC or CTC detection using the SE-iFISH platform. The experiment was performed according to the manufacturer’s protocol (Cytelligen, San Diego, CA, USA) with minor modifications. Briefly, for aDTCs or CTCs detection, ascitic fluid or peripheral blood samples were collected in tubes containing ACD anticoagulant (Becton Dickinson, Franklin Lakes, NJ, USA). The collected samples were then centrifuged at 350–400 g for 15 min. The sedimented cells were mixed with hCTC buffer, loaded on the non-hematopoietic cell separation, and centrifuged at 350 g for 6 min. The entire solution above the red blood cells (RBCs) layer was then collected and incubated with immuno-magnetic beads conjugated with a cocktail of anti-leukocyte monoclonal antibodies (Cytelligen, San Diego, CA, USA) for 20 min. White blood cells (WBCs) bound to immuno-beads were removed using a magnetic separator. The solution free of magnetic beads was collected, washed using phosphate-buffered saline (PBS), and spun twice to remove unspecific binding mAbs. Thereafter, the sedimented cells were processed for iFISH.
The dried monolayer cells on the coated aDTC/CTC slides were hybridized with CEP8 Spectrum Orange (Vysis, Abbott Laboratories, Chicago, IL, USA). Samples were subsequently incubated with anti-CD45 mAb conjugated with Alexa Fluor (AF) 594 (Cytelligen, San Diego, CA, USA). After washing, the samples were mounted using mounting media and scanned and analyzed with the automated Metafer-ifluorescence in situ hybridization (FISH)® 3D scanning (Carl Zeiss, Oberkochen, Germany) and image analysis system (MetaSystems, Altlus-sheim, Germany), FISH was performed using a centromere probe 8 (CEP8, Vysisy and Abbott, Abbott Park, IL, USA). In SE-iFISH platform, aneuploid Chr8 was employed as a marker for tumor cell confirmation due to the heterogenous expressions of epithelial and mesenchymal markers on DTCs (Supplementary Fig. S2). Overall, the aDTCs/CTCs with > disomy 8 were defined as aneuploids. Moreover, aDTCs/CTCs were defined as DAPI+ and CD45− with aneuploid Chr8 [17, 18].
Single-cell RNA sequencing
For scRNA-seq, single-cell suspensions in PBS (HyClone) with a concentration of 2 × 105 cells/mL were firstly prepared and then loaded onto microfluidic devices using the Singleron Matrix® Single Cell Processing System, and scRNA-seq libraries were constructed according to the GEXSCOPE® protocol using the GEXSCOPE® Single-Cell RNA Library Kit (Singleron Biotechnologies Köln, Germany). The individual libraries were diluted to 4 nM and pooled for sequencing on the Illumina Novaseq 6000 with 150-bp paired-end reads.
Primary analysis of raw read data
Raw reads obtained from the scRNA-seq were processed to generate gene expression matrixes using the CeleScope v1.3.0 (https://github.com/singleron-RD/CeleScope), an internal pipeline. Briefly, the raw reads were processed with the CeleScope to remove low-quality reads. The raw reads were first processed with fastQC v0.11.4 [19] and fastp (https://github.com/OpenGene/fastp) to remove low-quality reads and trim the poly-A tail and adapter sequences. The cell barcode and unique molecular identifier (UMI) were extracted. Thereafter, we used STAR v2.5.3a (https://github.com/alexdobin/STAR) to map the reads to the reference genome GRCh38 (ensemble version 92 annotation). The UMI and gene counts of each cell were obtained using Counts v1.6.2 (https://subread.sourceforge.net/featureCounts.html), and these were used to generate the expression matrix files for subsequent analysis.
Quality control, dimension reduction, and clustering
Scanpy v1.8.2 (https://scanpy.readthedocs.io/en/stable/) was used for quality control, dimensionality reduction, and clustering under Python 3.7. Finally, the cell clusters were visualized using the Uniform Manifold Approximation and Projection (UMAP). The details please see the supplementary materials and methods.
Differentially expressed gene (DEG) analysis
To identify DEGs, we used the Seurat Find Markers function based on the Wilcox likelihood-ratio test with default parameters, and we selected genes expressed in > 10% of cells in a cluster and with an average log (Fold Change) value > 0.25 in DEGs. For the cell type annotation of each cluster, we combined the expression of canonical markers found in DEGs based on the Scanpy literature and displayed the expression of markers of each cell type with heatmaps/dot plots/violin plots that were generated with the Seurat DoHeatmap/DotPlot/Vlnplot function. The mean expression of each cluster/sample was calculated using the Seurat Average Expression function. Doublet cells were identified as expression markers for different cell types and removed manually.
Cell type annotation and cell subtype identification
The cell type identity of each cluster was determined with the expression of the canonical markers found in the DEGs using the SynEcoSys database (Supplementary Table S1). In the scRNA-seq test cohort, we further subclustered the epithelial cells, T cells, MPs, and macrophages at resolutions 0.8, 1.0, 1.2, and 0.2, respectively. For the scRNA-seq validation cohort, we subclustered MPs and macrophages at resolutions 1.2 and 0.5, respectively.
scRNA-seq-based copy number variation (CNV) detection
The InferCNV package was used to detect CNVs in subpopulations of malignant epithelial cells (https://jlaffy.github.io/infercna). Non-malignant cells (mononuclear phagocytes [MPs], T cells, and B cells) were used as baselines to estimate the CNVs of malignant cells. The genes expressed in over 20 cells were sorted according to their loci on each chromosome. The relative expression values were centered to one using a 1.5 standard deviation from the residual-normalized expression values as the ceiling. A slide window size of 101 genes was used to smooth the relative expression on each chromosome to remove the effect of the gene-specific expression.
Trajectory analysis
Trajectory analysis was performed to track cell transition statuses. Cell data were reprocessed to remove low-UMI count genes or low-quality cells and were renormalized for the library size using the R package Monocle. After completing the quality control process, dimensional reduction and trajectory construction were conducted. The cells were placed on a pseudotime trajectory using the order obtained from the cell function. The pseudotime trajectory was inferred from the root cells that comprised the annotated macrophages. The differentiation trajectory of the macrophage subpopulations was reconstructed using Monocle 2 (https://github.Scylardor/Monocle2). Highly variable genes were used to sort cells according to spatial‐temporal differentiation. Moreover, we used the DDR Tree (Discriminative Dimensionality Reduction via learning a Tree) (https://github.com/cole-trapnel-lab/DDRTree) to perform FVF and dimension reduction. Finally, the trajectory was visualized using the plot cell trajectory function.
Cell–cell interaction analysis
Cell–cell interaction analysis was performed using CellPhoneDB v2.1.0 (https://github.com/Teichlab/cellphonedb) based on the known receptor–ligand interactions between the two cell types/subtypes. The cluster labels of all cells were permuted randomly 1000 times to calculate the null distribution of the average ligand-receptor expression levels of the interacting clusters. The individual ligand or receptor expression was accorded a threshold value with the cutoff value based on the average log gene expression distribution for all genes across all cell types. The significant cell–cell interactions were defined with a P-value of < 0.05 and an average log expression of > 0.1, which were visualized with the Circlize v0.4.10 R package (https://jokergoo.github.io/2020/06/14/changes-in-circlize-0.4.10/).
In vitro culturing of ascitic-derived primary tumor cells
Ascitic fluid was collected in sterile containers and used immediately to establish the primary cultures. The details please see the supplementary materials and methods.
Construction of TurboID biotin labeling system and interaction proteomic analysis
The TurboID biotin labeling system [20, 21] was used to biotinylate cytokines in ascites supernatant that interact with in vitro cultured ascites tumor cells. Briefly, ascites tumor cells were firstly transfected with lentivirus expressing TurboID (detailed procedures in Supplementary Materials and Methods). When incubating the TurboID-expressed ascitic tumor cells with their matched ascitic supernatants, proteins interacting with ascitic tumor cells in supernatants were near TurboID and were thereby biotinylated. Accordingly, streptavidin magnetic beads were utilized to pull down the biotinylated proteins. Moreover, all enriched biotinylated proteins were analyzed by liquid chromatography-mass spectrometry/mass spectrometry (LC–MS/MS) for further proteomic analysis. Procedures for LC–MS/MS detection and data analysis are shown in supplementary materials and methods.
Flow cytometric analysis
All antibodies used in flow cytometric analysis and the manufacturers’ information are listed in supplementary materials and methods.
Enzyme-linked immunosorbent assay (ELISA)
All the ELISA kits used are listed in supplementary materials and methods.
Western blot
All antibodies used in western blotting are listed in supplementary materials and methods.
Statistical analysis
All statistical analyses were performed using SPSS 21.0 (IBM Corp., NY, USA) or GraphPad Prism V8 (GraphPad Software, San Diego, CA, USA). For scRNA-seq data analysis, cell distribution comparisons between the two groups were performed using unpaired two-tailed Wilcoxon rank-sum tests. The comparison of the gene expression or gene signature between the two groups of cells was performed using the unpaired two-tailed Student’s t-test. Paired two-tailed Wilcoxon rank-sum tests were used to compare cell distribution between Group 1 and Group 2 and between ascites and matched PB samples. All statistical analyses and visualizations were conducted in R. The statistical tests used in the figures are indicated in the figure legends, and statistical significance was set at P-values < 0.05.
Results
Tumor cell-extrinsic dysfunctions also regulate aDTC immune evasion
Previous bulk transcriptional sequencing (RNA-seq) identified the overexpressed immune checkpoints TIM-3 and VISTA in ascitic cells of patients with PM-GC, indicating ascitic cells’ high immune escape ability [9]. To re-confirm this, aDTCs from ascites and CTCs from paired PB samples of 33 treatment-naïve patients with PM-GC were enriched via the previously established SE-iFISH platform (SE-iFISH cohort, Supplementary Fig. S1 and Table S2). Additionally, a pairwise comparison of the expression of PD-L1, another immune checkpoint marker mediating immune escape [22, 23], was conducted on enriched aDTCs or CTCs. The enumeration total and expression levels of PD-L1+ on aDTCs or ascites-disseminated microemboli (aDTMs), also known as ascites-disseminated tumor cell clusters aggregated with two or more aDTCs, were all higher than those of CTCs or circulating tumor microemboli (CTMs) [24] (Fig. 1a–d). In individual patients, the expression level of PD-L1 on aDTCs and aDTMs were augmented compared with that on paired CTCs and CTMs (Fig. 1e).
Besides enumeration and expression levels, the karyotypic characteristics of PD-L1+ on aDTCs and CTCs are completely distinct. PD-L1+ CTCs are predominantly multiploid chromosome 8 (chr8) (CTCmulti), whereas PD-L1+ aDTCs are mainly triploid chr8 (aDTCtri), indicating an elevated therapeutic tolerance of PD-L1+ aDTCs (Fig. 1f) [25]. Moreover, the prognostic analysis of the SE-iFISH cohort (Cohort-1) confirmed shorter overall survival (OS) of patients with positive pre-therapeutic PD-L1+ aDTCs (PD-L1+ aDTCs ≥ 1 cell/6 mL, Fig. 1g). These results are in line with previous findings and further demonstrated that the overexpressed PD-L1 on aDTCs is involved in aDTC immune evasion.
Current studies on PD-L1+ tumors suggest a paradoxical role of the PD-L1 expression on the PD-1/PD-L1 blockade efficiency [26, 27]. Although higher pre-therapeutic PD-L1 levels in primary tumors are considered an indicator of increased sensitivity to anti-PD-1/PD-L1 therapy, the re-acquisition or uncontrollable PD-L1 expression on either tumor or immune cells is associated with therapeutic resistance to PD-1/PD-L1 blockades [27]. Our results indicated that disruption of tumor-cell intrinsic aggressiveness by systematic chemotherapies could not abolish overexpressed PD-L1 on aDTCs, thereby demonstrating that PD-L1+ aDTCs were still detectable in most post-therapy ascites in 5 of 33 enrolled patients (Fig. 1h). This implies that re-acquisition or uncontrolled PD-L1 overexpression may be regulated by tumor cell-intrinsic mechanisms and tumor cell-extrinsic mechanisms. Therefore, inhibiting only tumor-cell intrinsic targets cannot completely curb aDTC immune escape.
MPs dominate the TME of aDTC-rich ascites
To comprehensively understand tumor-cell extrinsic mechanisms underlying aDTC immune evasion, we cataloged the cell components of ascites and paired PB samples collected from seven treatment-naïve patients with PM-GC (scRNA-seq test cohort, Supplementary Fig. S1 and Supplementary Table S3) by leveraging single-cell transcriptional sequencing (scRNA-seq). Overall, 144,522 cells from all 14 ascites samples and matched PB samples, which passed multiple quality controls, were further clustered using Seurat. Overall, eight cell clusters, including MPs [28], epithelial cells [29], T cells [30], B cells [31], platelets [32], fibroblasts [33], erythrocytes [32], and neutrophils [34], were annotated using canonical markers (Fig. 2a, Supplementary Fig. S3A, and Supplementary Table S1). Among these, epithelial cells and MPs were mainly from ascites samples, while T and B cells were from both ascites and PB samples (Fig. 2b, Supplementary Fig. S3B-C).
Since aDTC presence is a prognosticator of an inferior OS in PM-GC (Supplementary Fig. S3D), we first inspected the malignant subsets in epithelial cells. In the predominantly enriched samples AS_1, AS_4, and AS_2, 16 epithelial cell clusters were identified (Fig. 2c and Supplementary Fig. S3C). Consistent with previous findings [10], the epithelial cells in the ascites samples from PM-GC patients were highly heterogenous, and each ascites sample comprised specific epithelial cell clusters. For instance, the epithelial cell clusters E2, E3, E4, and E9 were only found in sample AS_1. Conversely, the clusters E6, E10, and E14 belonged exclusively to sample AS_4 (Fig. 2c and Supplementary Fig. S3E). High diversity of CNVs was identified in the individual clusters, further demonstrating malignancy in all 16 epithelial cell clusters; accordingly, we referred to all epithelial cell clusters as aDTC clusters (Fig. 2d). The 17q copy number gain, which is considered a unique event in tumor cells from the stomach [10], was identified in most aDTC clusters in our study, confirming the stomach tumor-specific origin of all detected aDTC clusters (Fig. 2d).
Regarding PD-L1 expression, we failed to recognize the transcriptional PD-L1 elevation in aDTC clusters, probably owing to the dropouts in scRNA-seq. However, PD-L1 protein overexpression on aDTCs was validated by SE-iFISH, as demonstrated by > 50% of aDTCs being detected as PD-L1-positive in five out of seven ascites samples (Fig. 2e).
We hypothesized that the upregulated PD-L1 on aDTCs and its immune escape mediation is modulated by immunosuppressive interactions between the cell-extrinsic immune TME and aDTCs. To demonstrate this, the immune components, especially in the aDTC-rich ascites samples (samples AS_1, AS_4, and AS_2: referred to as ASSubtype 1), were analyzed. MPs, rather than T cells, were overwhelmingly infiltrated in the TME of the aDTC-rich ascites samples (Fig. 2f and Supplementary Fig. S3C). Moreover, aDTC quantification in aDTC-rich ascites showed an inverse correlation with the presence of MPs, implying robust communications between aDTCs and MPs (Fig. 2f).
In aDTC-deficient ascites, MPs and T cells may exist exclusively in the TME of the ascitic fluid, which further shapes the two heterogenous TME subtypes of ascites: ASSubtype 2 and ASSubtype 3. In ASSubtype 2 ascites, the TME is MP-dominant, with < 10% T cells being infiltrated (sample AS_3, AS_6, and AS_5, Fig. 2f). In ASSubtype 3 ascites, a high presence of T cells in the TME impedes MP infiltration (sample AS_7, Fig. 2f). These results indicated that MPs and T cells might independently modulate the development of ascites in patients with PM-GC.
Ascitic TAMs form a continuum transitioning from cathepsin (CTS)high to complement 1q (C1Q) high
Physiologically, a macrophage plays a critical role in maintaining immune homeostasis in the peritoneal cavity [1]. This raises the question of whether TAMs are hub MPs involved in immunosuppressive communication with aDTCs in PM-GC ascites. Moreover, macrophages account for the highest MP proportion, especially in the aDTC-rich ASSubtype 1 ascites (Fig. 3a, b and Supplementary Fig. S4A). Additionally, the upregulated DEGs identified in macrophages, including APOE, C1QB, APOC1, C1QC, C1QA, SPP1, LYVE1, LGMN, and cathepsin L (CTSL), are all anti-inflammatory, further conferring their immunosuppressive function; accordingly, we referred to all annotated macrophages as TAMs (Fig. 3c). To disclose the specific function of the individual TAM lineage clustered by unsupervised learning (Fig. 3d and Supplementary Fig. S4B), we initially examined canonical M1 and M2 signatures in each TAM cluster [16]. Nevertheless, all TAM clusters failed to fall into the M1/M2 dichotomy (Supplementary Fig. S4C and Supplementary Table S4). However, when comparing DEGs of TAMs from the MP clustering (Fig. 3c) in the individual TAM lineage, we noted the presence of transitionally varied expression patterns of the C1Q-associated genes C1QA, C1QB, and C1QC and CTS-associated genes CTSA, CTSD, CTSL, which can confer three TAM lineages perfectly: CTShigh/C1Qhigh (Macro 6), CTSlow/C1Qhigh (Macro 3 and Macro 2), and CTShigh/C1Qlow (Macro 1, Macro 4, and Macro 5) (Fig. 3e). These indicated that the expressional variation of CTS and C1Q genes on ascitic TAMs are a continuum instead of a dichotomic polarization.
Therefore, we investigated how this continuum of gene expression varied following TAM lineage differentiation. The trajectory of TAM lineages analyzed using Monocle 2 is shown in Fig. 3f. The five developmental states of TAM lineages were determined. The differentiation of ascitic TAMs commenced from the CTShigh/C1Qhigh Macro 6, evolving to CTShigh TAM lineages (Macro 1, 4, and 5) at intermediate states (Fig. 3g and Supplementary Fig. S4D). Distinct from the CTShigh TAM lineages that exist in all states thereafter, the C1Qhigh TAM lineages (Macro 2, and 3) were only developed in the terminal state (Fig. 3g and Supplementary Fig. S4D). Further insight into the expression of C1Q and CTS genes following pseudotime confirmed that C1Q gene levels were only elevated at the terminal pseudotime. This was contrary to the CTS genes, which showed a terminal decrease after an increase at the intermediate pseudotime (Fig. 3h).
Altogether, the obtained results support the view that ascitic TAMs undergo a lineage transition from the CTShigh to C1Qhigh subtype (CTS-to-C1Q transition) and that the CTShigh lineages are TAM precursors, which differentiate terminally toward the C1Qhigh lineages.
TAM transition from CTShigh to C1Qhigh modulates different aDTC dissemination phases
Having uncovered the specific CTS-to-C1Q transition in ascitic TAMs, we next investigated how the TAMs in different transitional states interact with aDTCs and influence their dissemination. To this end, the cell-to-cell communications (CCC) between TAMs and aDTCs were analyzed using the Cell-PhoneDB in an aDTC-rich AS Subtype 1 ascites. The interaction strength between TAM lineages and aDTCs is mapped in Fig. 4a and Supplementary Fig. S4E, which show that the interaction strength of aDTCs with CTShigh (Macro 1) and C1Qhigh (Macro 2) lineages is comparable (Fig. 4a). Similarly, a comparison of the interaction types and directionality between the CTShigh or C1Qhigh lineages and aDTCs did not show any difference (Fig. 4b and Supplementary Fig. S4F). These results inferred that CTShigh and C1Qhigh TAMs crosstalk robustly with aDTCs. CTShigh or C1Qhigh TAMs are more likely the signal-sending cells propagating secreted signaling to modulate aDTC behavior.
Accordingly, we examined the secreted crosstalk between CTShigh or C1Qhigh TAMs and aDTCs. Figure 4c, d displays the top 30 difference or specifically interaction pairs between TAM lineages and aDTCs. CTShigh and C1Qhigh TAMs generate immunosuppressive interactions with aDTCs via predominantly secretion of SPP1 [35], FN1 [36], TIMP1 [37], or upregulation of CD74 [38], all of which foster tumor-cell metastasis (Fig. 4c). Specifically, CTShigh TAMs are inclined to secrete CXCL2 [39], LAMC1 [40], and NRP1 [41], which shape the TME of pre-metastatic niches and facilitate angiogenesis [42, 43]. Additionally, CTShigh TAMs secrete EPHB2, which contributes crucially to tumor-cell stemness via engagement to its receptor EFNB1 [44]. C1Qhigh TAMs interact principally with aDTCs via the epiregulin-epidermal growth factor receptor (EGFR) [45] and CD226-NECTIN2 receptor–ligand pairs, which are involved in tumor-cell survival and proliferation [46, 47] (Fig. 4d).
Collectively, we suggested that CTShigh TAMs likely regulate the initial phases of aDTC dissemination via programming pre-metastatic TME and attracting aDTCs homing into ascites, while the stepwise transition from CTShigh to C1Qhigh TAMs triggers and maintains the overproliferation of homed aDTCs in ascites.
C1Qhigh TAMs drive aDTC immune evasion in the proliferative phase of ascitic metastasis
Due to the crucial role of the CTS-to-C1Q transition in the TAM-aDTC crosstalk, we next investigated whether this transition was also involved in the aDTC PD-L1-mediated immune escape, as demonstrated in the SE-iFISH cohort (Fig. 1). By analyzing RNA-seq data of 48 metastatic GCs from The Cancer Genome Atlas (TCGA) database, we first noted that C1Q genes (C1QA, C1QB, and C1QC), rather than CTS genes (CTSA, CTSB, CTSD, and CTSL), showed a positive correlation with the PD-L1 levels (Fig. 4e). To confirm further the involvement of C1Qhigh TAMs in the PD-L1 upregulation on aDTCs, we cultured aDTCs from eight ascites of PM-GC samples in vitro (Fig. 4f). Treatments of the ascitic supernatants significantly enhanced PD-L1 expression on the in vitro cultured aDTCs (Fig. 4g, h and Supplementary Fig. S4G-H). Similarly, NECTIN2, which interact specifically with C1Qhigh TAMs, expressions were upregulated in ascites-treated aDTCs (Fig. 4g, i, Supplementary Fig. S4G and S4I). This synchronous upregulation of PD-L1 and C1Qhigh TAM-interacting proteins was also observed in ascites-treated GC cell lines HGC27, MKN45, and SNU1 (Fig. 5a–c), confirming that PD-L1 upregulation on aDTCs occurs in the proliferative phase of ascitic metastasis, coincident with the C1Qhigh TAMs-driven overproliferation of aDTCs.
Complement protein C1q participates in PD-L1 upregulation on aDTCs driven by C1Qhigh TAMs
Next, we investigated whether C1Qhigh TAMs modulate PD-L1 and NECTIN2 overexpression on aDTCs by secreting complement protein C1q in the SE-iFISH cohort. The levels of C1q and C3 in ascites both showed a positive correlation with the number of PD-L1+ aDTCs and aDTMs (Fig. 5d), suggesting that the activation of the appropriate classical complement pathway underlies PD-L1 upregulation on aDTCs.
To further illustrate the direct interaction of C1q and ascitic tumor cells, the biotin ligase TurboID labeling system [28] was transfected into in vitro cultured aDTCs (Fig. 5e). The overexpressed TurboID biotinylates neighboring cytokines in ascites supernatant that interacts with aDTCs. Further proteomic analysis of the biotinylated cytokines enriched by streptavidin magnetic beads (Fig. 5f, g) showed that complement proteins C1QA, C1QB, C1QC, C3, and C4 were all enriched in ascites-treated cells (Fig. 5h), demonstrating the direct crosstalk between components in the complement pathway and ascitic tumor cells.
The next question is whether the engagement of complement proteins influences PD-L1 and NECTIN2 expression on ascitic tumor cells. To address this, we compared PD-L1 and NECTIN2 expressions on GC cell lines treated with either singular ascitic supernatants or their combination with the recombinant C1q protein. Adding recombinant complement C1q protein to GC cell lines HGC27, MKN45, and SNU1 treated by ascites #2 can further augment PD-L1 and NECTIN2 upregulation induced by singular ascitic supernatants (Fig. 5i–k).
To further confirm the role of C1Qhigh TAMs, GC cell line MKN45 and SNU1 were co-cultured with THP-1 derived macrophages in the presence or absence of C1NH, the human recombinant C1 inhibitor used to abolish the function of secreted C1q from macrophages (Fig. 5l). As shown in Fig. 5m–o, addition of C1NH significantly mitigates both PD-L1 and NECTIN2 expression on MKN45 and SNU1, which further confirms that C1q secreted by co-cultured macrophages mediates the activation of complement pathway, participating in the PD-L1 and NECTIN2 upregulation and promoting aDTCs immune evasion in PM-GC.
CTS-to-C1Q transition of TAMs fosters therapeutic resistance of PM-GC
Having determined the contribution of the CTS-to-C1Q transition of TAMs to aDTC dissemination and immune escape, we next investigated whether this transition could lead to therapeutic resistance in patients with PM-GC. To validate the CTS-to-C1Q transition of ascitic TAMs specifically, we used another independent cohort containing both treatment-naïve and paired therapeutically resistant ascites samples from eight patients with PM-GC (scRNA-seq validation cohort, Supplementary Fig. S1 and Supplementary Table S5). Figure 6a displays TAM lineages clustered from 18 ascites samples from the scRNA-seq validation cohort. Comparison of TAM lineages from treatment-naïve or therapeutically resistant ascites patients highlights cluster Macro 4 as the only therapeutically resistant (TR) TAM lineage, which was determined by its proportional elevation in the therapeutically resistant ascites (Fig. 6b, c and Supplementary Fig. S5A). Transcriptional levels of C1QA, C1QB, and C1QC showed a marked increase in Macro 4 (Fig. 6d, e). Conversely, neither of the CTS genes showed variations in Macro 4 compared with the other TAM lineages (Fig. 6e).
Next, we investigated whether C1Qhigh TR TAMs transitioned from the CTShigh lineages, leading to therapeutic resistance. Figure 6f shows the trajectory of the TAM differentiation following therapeutic resistance. The therapeutically sensitive (TS) Macro 5, identified by its large decrease in TR ascites level (Fig. 6c), is predominant in the TAM precursor lineage, presenting in the initial state (State 1 in Fig. 6f and Supplementary Fig. S5B-C). Without treatments, Macro 5 directly develops to another TS lineage, Macro 8, existing mainly in State 5 (Fig. 6g and Supplementary Fig. S5B-D). Other TS TAM lineages (Macro 6 and Macro 9) showed progression similar to that in State 5 (Fig. 6g). However, under therapeutic pressures, Macro 5 differentiates distinctly into the TR TAM lineage Macro 4 at the bifurcated States 2, 6, and 7 (Fig. 6f, g and Supplementary Fig. S5D). Further insight into the variations in C1Q and CTS gene levels following pseudotime shows that the CTS genes showed high expression in the initial pseudotime, when TS lineages were predominant. However, this overexpression of the CTS genes gradually transitioned to an overexpression of the C1Q genes at the intermediate pseudotime when the TR TAM lineage was developed (Fig. 6h).
Collectively, the results demonstrated that the TAM transition from the CTShigh to C1Qhigh lineages facilitates the development of therapeutic resistance and ascitic progression in patients with PM-GC.
Ascitic CD8+ T cells are dysfunctional, showing limited cytotoxic activity
As mentioned previously, the exclusive infiltration of T cells in ASSubtype 3 ascites suggests their independent function in ascites development. Therefore, we explored the specific characteristics of ascitic T cells based on our scRNA-seq data from the scRNA-seq test cohort (seven treatment-naïve ascites and paired PB samples, Supplementary Fig. S1 and Supplementary Table S3). Overall, 12 T-cell clusters were identified in the ascites and paired PB samples (Fig. 7a and Supplementary Fig. S6A). The most variant lineages between ascites and PB were the effector CD8 T-cell clusters (Fig. 7b). The effector CD8 T-cell subpopulations Eff CD8 C6, C10, and C1 in ascites reduced quantitatively compared with those in PB. Conversely, the Eff CD8-C7 proportion showed significant elevation, especially in ASSubtype 3 ascites, compared with that in PB (Fig. 7c and Supplementary Fig. S6B).
Besides the effector CD8 T cells, CD25+/CD127low/− Treg cells were observed to infiltrate differentially in ascites and PB samples in the fluorescence-activated cell sorting analysis of ascites in the SE-iFISH cohort. The CD25 + /CD127low/- Tregs proportion was significantly higher in ascites than in PB (Fig. 7d, e).
Due to the heterogeneity of effector CD8 T-cell subsets, we next compared DEGs of effector CD8 T cells from ascites and PB samples. The genes relevant to T-cell-mediated cytotoxicity, including NKG7, GZMH, GZMB, and GNLY, were downregulated in ascitic CD8+ T cells. Inversely, TPT1, GZMK, KLRB1, and ribosomal protein-associated genes were upregulated (Fig. 7f). Further examination of DEGs from the individual effector CD8 T-cell clusters confirmed that Eff CD8-C7, which were enriched mainly in ascites, lacked cytotoxicity-associated gene expression. However, they presented higher GZMK expression than did Eff CD8-C1, C10, and C6, which existed predominantly in PB (Fig. 7g and Supplementary Fig. S6C). GZMK has a high expression on precursor-exhausted T cells [48]. Moreover, KLRB1 and TPT1 upregulation indicated a reduction in the cytotoxicity of CD8 T cells [49, 50]. Therefore, we conclude that the CD8+ T cells infiltrating in ascites are “senseless CD8+ T cells,” which have lost their antitumor capability.
Discussion
Here, the heterogenous immune TME of ascites from patients with PM-GC was investigated according to three ascites subtypes: ASSubtype 1, characterized as aDTC-rich ascites with an MP-dominant TME; ASSubtype 2, with the same MP-dominant TME, but with a lower aDTC level than that of ASSubtype 1; and ASSubtype 3, with exclusive T-cell infiltration in the TME. For the first time, in TAM-dominant ascites, we identified a specific CTS-to-C1Q transition in ascitic TAMs, prompting aDTC dissemination and immune escape. CTShigh TAMs were identified as precursors for the initial construction of the pro-metastatic TME and to facilitate aDTCs homing in ascites. The later transitioned C1Qhigh TAMs were of a terminal lineage that promoted the overproliferation, PD-L1-mediated immune evasion, and therapeutic resistance of the homed aDTCs in ascites. Moreover, in T-cell-dominant ascites, increased T-cell infiltration did not infer an “immune-hot” TME. The effector CD8+ T cells enriched with ascites were predominantly precursor-exhausted CD8+ T cells with limited antitumor cytotoxicity.
C1Qhigh TAMs are immunosuppressive components in clear-cell renal cell carcinoma, hepatocellular carcinoma, breast cancer, and osteosarcoma [51,52,53,54]. However, the development of C1Qhigh TAMs and mechanisms underlying their immunosuppression remain unclear. Here, we demonstrated that C1Qhigh TAMs in ascites from patients with PM-GC are not pre-existing but are terminally differentiated from CTShigh TAM precursors. Regarding the immunosuppressive mechanisms, we highlighted the interaction between C1Qhigh TAMs and aDTCs, showing that C1Qhigh TAMs can trigger the PD-L1-mediated immune escape of aDTCs via secreted signaling, including C1q, and the associated complement pathway activation. Concurrently, C1Qhigh TAMs improve the overproliferation of aDTCs via the indirect upregulation of NECTIN2 and EGFR. Besides driving the pro-metastatic process, C1Qhigh TAMs induce therapeutic resistance in patients with PM-GC. TR TAM lineages all harbor significantly high expression of the C1Q genes.
The characteristics and functions of T cells infiltrating the ascites of PM-GC remain unknown. Our study is the first to suggest that the effector CD8+ T cells, predominantly enriched in T-cell-dominant ascites, harbored the upregulated GZMK, which was recently identified as a marker of the precursor-exhausted T cells in non-small-cell lung cancer [45]. Ascitic GZMK+CD8+ T cells in PM-GC lack the expression of cytotoxicity-associated genes, indicative of their loss of antitumor function. However, due to the small sample size, this study did not explore the mechanisms underlying the development of T-cell-dominant ascites were not explored in this study due to the small sample size. Limited aDTCs were detected in T cell-dominant ascites compared with that in MP-dominant ascites, suggesting that ascitic T cells may not interact primarily with the aDTCs. Further investigation on how the GZMK+CD8+ T cells in ascites contribute to ascites development still needs to be conducted.
In conclusion, our data have deepened the current understanding of the immune TME of ascites in PM-GC. We highlighted the interplay between TAMs and aDTCs and uncovered the mechanisms underlying the ascitic metastasis driven by the CTS-to-C1Q TAM transition.
Availability of data and materials
All other data are available in the article and its Supplementary files or from the corresponding author upon reasonable request. Source data are provided with this paper. Further information and reasonable requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Lin Shen (shenlin@bjmu.edu.cn).
Abbreviations
- aDTMs:
-
Ascites-disseminated microemboli
- aDTCs:
-
Ascites-disseminated tumor cells
- CCC:
-
Cell-to-cell communications
- C1NH:
-
Human recombinant C1 inhibitor
- C1Q:
-
Complement 1q
- CNV:
-
Copy number variations
- CTMs:
-
Circulating tumor microemboli
- CTCs:
-
Circulating tumor cells
- CTS:
-
Cathepsin
- CTSL:
-
Cathepsin L
- CSC:
-
Cancer stem cell
- DEG:
-
Differentially expressed gene
- EGFR:
-
Epiregulin-epidermal growth factor receptor
- ELISA:
-
Enzyme-linked immunosorbent assay
- FVF:
-
Find variable features
- GC:
-
Gastric cancer
- HIPEC:
-
Hyperthermic intraperitoneal chemotherapy
- LC–MS/MS:
-
Liquid chromatography-mass spectrometry/mass spectrometry
- MSI-H:
-
Microsatellite instability-high
- OS:
-
Overall survival
- PB:
-
Peripheral blood
- PBMCs:
-
Peripheral blood mononuclear cells
- PBS:
-
Phosphate-buffered saline
- PM:
-
Peritoneal metastasis
- PMA:
-
Phorbol-12-myristate-13-acetate
- PM-GC:
-
GC with peritoneal carcinomatosis
- PVDF:
-
Polyvinylidene fluoride
- RBCs:
-
Red blood cells
- RCLB:
-
RBC lysis buffer
- RNA-seq:
-
Bulk transcriptional sequencing
- SDs:
-
Standard deviations
- scRNA-seq:
-
Single-cell RNA sequencing
- SE-iFISH:
-
Subtraction enrichment and immunostaining-fluorescence in situ hybridization
- TAMs:
-
Tumor-associated macrophages
- TGF-β:
-
Transforming growth factor-β
- TGF-β1:
-
Transforming growth factor-β1
- TME:
-
Tumor microenvironment
- TCGA:
-
The Cancer Genome Atlas
- TR:
-
Therapeutically resistant
- TS:
-
Therapeutically sensitive
- UMAP:
-
Uniform Manifold Approximation and Projection
- UMI:
-
Unique molecular identifier
References
Cortés-Guiral D, Hübner M, Alyami M, et al. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):91.
Koemans WJ, Lurvink RJ, Grootscholten C, et al. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24(4):800–9.
Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635–48.
Ulas EB, Dickhoff C, Schneiders FL, et al. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. ESMO Open. 2021;6(5): 100244.
Topalian SL, Hodi FS, Brahmer JR, et al. Five-Year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with Nivolumab. JAMA Oncol. 2019;5(10):1411–20.
Diaz LA, Le DT, Yoshino T, et al. KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC). J Clin Oncol. 2018;36(4_suppl):S877.
Fucà G, Cohen R, Lonardi S, et al. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer. 2022;10(2): e004001.
Tanaka Y, Chiwaki F, Kojima S, et al. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer. 2021;2(9):962–77.
Wang R, Song S, Harada K, et al. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 2020;69(1):18–31.
Wang R, Dang M, Harada K, et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021;27(1):141–51.
Sathe A, Grimes SM, Lau BT, et al. Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment. Clin Cancer Res. 2020;26(11):2640–53.
Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021;21(8):526–36.
Chkourko GH, Diedrich J, MacDougald OA, et al. Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression. Obes Rev. 2016;17(11):1015–29.
Fan QM, Jing YY, Yu GF, et al. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 2014;352(2):160–8.
Shi Y, Ping YF, Zhou W, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017;8:15080.
Eum HH, Kwon M, Ryu D, et al. Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. Exp Mol Med. 2020;52(12):1976–88.
Liu X, Zhang Z, Zhang B, et al. Circulating tumor cells detection in neuroblastoma patients by EpCAM-independent enrichment and immunostaining-fluorescence in situ hybridization. EBioMedicine. 2018;35:244–50.
Li Y, Zhang X, Liu D, et al. Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance. Clin Cancer Res. 2018;24(21):5261–71.
Butler A, Hoffman P, Smibert P, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411–20.
Branon TC, Bosch JA, Sanchez AD, et al. Efficient proximity labeling in living cells and organisms with TurboID. Nat Biotechnol. 2018;36(9):880–7.
Li Y, Liu S, Cao L, et al. CBRPP: a new RNA-centric method to study RNA-protein interactions. RNA Biol. 2021;18(11):1608–21.
Park HS, Kwon WS, Park S, et al. Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. J Immunother Cancer. 2019;7(1):268.
Hosseinzadeh R, Feizisani F, Shomali N, et al. PD-1/PD-L1 blockade: prospectives for immunotherapy in cancer and autoimmunity. IUBMB Life. 2021;73(11):1293–306.
Umer M, Vaidyanathan R, Nguyen NT, et al. Circulating tumor microemboli: progress in molecular understanding and enrichment technologies. Biotechnol Adv. 2018;36(4):1367–89.
Chen Y, Li Y, Qi C, et al. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients. Cancer Lett. 2021;517:78–87.
Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.
Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.
Combes AJ, Courau T, Kuhn NF, et al. Global absence and targeting of protective immune states in severe COVID-19. Nature. 2021;591(7848):124–30.
Smillie CS, Biton M, Ordovas-Montanes J, et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019;178(3):714–30.
Zeng Y, Liu C, Gong Y, et al. Single-cell RNA sequencing resolves spatiotemporal development of pre-thymic lymphoid progenitors and thymus organogenesis in human embryos. Immunity. 2019;51(5):930–48.
Schafflick D, Xu CA, Hartlehnert M, et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun. 2020;11(1):247.
Silvin A, Chapuis N, Dunsmore G, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182(6):1401–18.
Dong R, Yang R, Zhan Y, et al. Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma. Cancer Cell. 2020;38(5):716–33.
Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070–6.
Qi J, Sun H, Zhang Y, et al. Single-cell and spatial analysis reveal interaction of FAP (+) fibroblasts and SPP1 (+) macrophages in colorectal cancer. Nat Commun. 2022;13(1):1742.
Xie Y, Liu C, Qin Y, et al. Knockdown of IRE1ɑ suppresses metastatic potential of colon cancer cells through inhibiting FN1-Src/FAK-GTPases signaling. Int J Biochem Cell Biol. 2019;114: 105572.
Ma B, Ueda H, Okamoto K, et al. TIMP1 promotes cell proliferation and invasion capability of right-sided colon cancers via the FAK/Akt signaling pathway. Cancer Sci. 2022;113:4244–57.
de Azevedo RA, Shoshan E, Whang S, et al. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020;9(1):1846915.
Di Mitri D, Mirenda M, Vasilevska J, et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 2019;28(8):2156–68.
Fang Y, Dou R, Huang S, et al. LAMC1-mediated preadipocytes differentiation promoted peritoneum pre-metastatic niche formation and gastric cancer metastasis. Int J Biol Sci. 2022;18(7):3082–101.
Jin Q, Ren Q, Chang X, et al. Neuropilin-1 predicts poor prognosis and promotes tumor metastasis through epithelial-mesenchymal transition in gastric cancer. J Cancer. 2021;12(12):3648–59.
Wild JR, Staton CA, Chapple K, et al. Neuropilins: expression and roles in the epithelium. Int J Exp Pathol. 2012;93(2):81–103.
Urbantat RM, Blank A, Kremenetskaia I, et al. The CXCL2/IL8/CXCR2 pathway is relevant for brain tumor malignancy and endothelial cell function. Int J Mol Sci. 2021;22(5):2634.
Leung HW, Leung C, Lau EY, et al. EPHB2 activates β-catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res. 2021;81(12):3229–40.
Peng S, Wang R, Zhang X, et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019;18(1):165.
Wang JB, Li P, Liu XL, et al. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. Nat Commun. 2020;11(1):6352.
Xu K, Wang R, Xie H, et al. Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast cancer lymph node metastasis. Oncogenesis. 2021;10(10):66.
Liu B, Hu X, Feng K, et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat Cancer. 2022;3(1):108–21.
Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184(2):404–21.
Hangai S, Kawamura T, Kimura Y, et al. Orchestration of myeloid-derived suppressor cells in the tumor microenvironment by ubiquitous cellular protein TCTP released by tumor cells. Nat Immunol. 2021;22(8):947–57.
Revel M, Sautès-Fridman C, Fridman WH, et al. C1q+ macrophages: passengers or drivers of cancer progression. Trends Cancer. 2022;8(7):517–26.
Yang J, Lin P, Yang M, et al. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma. Genome Biol. 2021;22(1):4.
Obradovic A, Chowdhury N, Haake SM, et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021;184(11):2988–3005.
Roumenina LT, Daugan MV, Noé R, et al. Tumor cells Hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol Res. 2019;7(7):1091–105.
Acknowledgements
This work was supported by Beijing Natural Science Foundation (7232016 to Y.L.); the National Natural Science Foundation of China (91959205 to L.S., 82203881 to Y.C.); Beijing Natural Science Foundation (Z200015 to XT.Z., 7222021 to Y.C.); The Capital Foundation of Medical Development (2020-1-1022 to XT.Z.); Wu Jieping Medical Foundation (320.6750.2021-02-15 to Y.C.)
Author information
Authors and Affiliations
Contributions
Y.L. and L.S. conceived of and designed the study. Y.L., L.J. and Y.C. wrote and edited the manuscript. Y.L. and Y.C. performed the SE-iFISH, J.Y. collected clinical samples. L.J. and J.L. performed western blot. J.L., Y.L, X.F., Y.C. and S.L. processed flow cytometry. J.X. and Y.J. performed scRNA-seq. Y.L., L.J., Y.C. and Y.J. analyzed scRNA data. X.Z., J.L. and L.S. advised on data processing.
Corresponding author
Ethics declarations
Ethical approval and consent to participate
The study was approved by the Institutional Ethics Committee of our hospital. Written consent forms were received from each patient before specimen collection.
Conflict of interest
J.X. and Y.J. are employees of Singleron Biotechnologies. Other authors declare no competing interests.
Consent for publication
Yes.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Li, Y., Jiang, L., Chen, Y. et al. Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis. Gastric Cancer 27, 519–538 (2024). https://doi.org/10.1007/s10120-024-01486-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-024-01486-6